Isolated regional chemotherapeutic perfusion oflimbs

Cover Page

Cite item

Full Text

Abstract

Among patients suffering from diseases such as skin melanoma, skin cancer and soft tissue sarcoma, there is a group with locally advanced forms. Standard treatment options may not be effective. For some patients, limbsparing approach is often not possible. Amputation decrease quality of life. Isolated regional perfusion - the method of temporary isolation of the affected limb with the implementation of cardiopulmonary bypass and chemotherapy agents loaded in it. The method of ILP was developed to be able to achieve regional concentrations of chemotherapeutic agents that are 15 to 25 times higher than can be reached with systemic administration, but without the systemic sideeffects. Melphalanbased ILP is associated with complete response rates of 40-50%, and overall response rates of 75-80%. When Tumor Necrosis Factor-alfa was introduced in the isolated limb perfusion model by Lejeune and Lienard in 1988, complete response rates of 80-90% were reported. Multicenter trials confirmed that TNFbased ILP was a highly effective new method of induction biochemotherapy for extremity soft tissue sarcomas with a 20-30% complete remission rate, a 50% partial remission rate and a limb salvage percentage of 80%. We treated 2 patients in RCRC N.N. Blokhin RAMS with isolated limb perfusion with melfalan and mild hyperthermia. Progression not observed for 9 months.

About the authors

M. D. Aliev

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Author for correspondence.
Russian Federation

B. I. Dolgushin

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

L. V. Demidov

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

T. K. Charatishvili

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

Y. V. Buydenok

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

B. Y. Narkevitch

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

D. V. Martynkov

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Email: generaloncology@rambler.ru
Russian Federation

A. A. Fedenko

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

B. Y. Bokhyan

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Aliev M.D., Dolgushin B.I., Demidov L.V., Charatishvili T.K., Buydenok Y.V., Narkevitch B.Y., Martynkov D.V., Fedenko A.A., Bokhyan B.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-66671 от  09.11.2009.